Urszula Karczmarczyk
Overview
Explore the profile of Urszula Karczmarczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krajewski S, Steczek L, Gotowicz K, Karczmarczyk U, Towpik J, Witkowska-Patena E, et al.
EJNMMI Res
. 2024 Jul;
14(1):63.
PMID: 38976101
Background: Positron emission tomography (PET) is now an established diagnostic method for myocardial perfusion imaging (MPI) in coronary artery disease, which is the main cause of death globally. The available...
2.
Rurarz B, Urbanek K, Karczmarczyk U, Raczkowska J, Habrowska-Gorczynska D, Koziel M, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067350
Despite the tremendous development of oncology, prostate cancer remains a debilitating malignancy. One of the most promising approaches to addressing this issue is to exploit the advancements of nanomedicine in...
3.
Rurarz B, Bukowczyk M, Gibka N, Piastowska-Ciesielska A, Karczmarczyk U, Ulanski P
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834867
Advances in nanomedicine bring the attention of researchers to the molecular targets that can play a major role in the development of novel therapeutic and diagnostic modalities for cancer management....
4.
Maurin M, Wyczolkowska M, Sawicka A, Sikora A, Karczmarczyk U, Janota B, et al.
Molecules
. 2022 Nov;
27(21).
PMID: 36364046
Despite significant advances in nuclear medicine for diagnosing and treating prostate cancer (PCa), research into new ligands with increasingly better biological properties is still ongoing. Prostate-specific membrane antigen (PSMA) ligands...
5.
Karczmarczyk U, Sawicka A, Garnuszek P, Maurin M, Wojdowska W
J Med Chem
. 2022 Apr;
65(9):6419-6430.
PMID: 35442675
There has been considerable interest in developing a monoclonal antibody (mAb) against-CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non-Hodgkin's lymphoma radioimmunotherapy. Therefore, many researchers have modified...
6.
Matusiak M, Rurarz B, Kadlubowski S, Wolszczak M, Karczmarczyk U, Maurin M, et al.
Pharmaceutics
. 2021 Aug;
13(8).
PMID: 34452201
Radiation crosslinking was employed to obtain nanocarriers based on poly(acrylic acid)-PAA-for targeted delivery of radioactive isotopes. These nanocarriers are internally crosslinked hydrophilic macromolecules-nanogels-bearing carboxylic groups to facilitate functionalization. PAA nanogels...
7.
DOnofrio A, Silva F, Gano L, Karczmarczyk U, Mikolajczak R, Garnuszek P, et al.
Front Med (Lausanne)
. 2021 Jun;
8:647379.
PMID: 34179038
Pre-targeting approaches based on the inverse-electron-demand Diels-Alder (iEDDA) reaction between strained trans-cyclooctenes (TCO) and electron-deficient tetrazines (Tz) have emerged in recent years as valid alternatives to classic targeted strategies to...
8.
Lankoff A, Czerwinska M, Walczak R, Karczmarczyk U, Tomczyk K, Brzoska K, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34071854
Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for...
9.
Karczmarczyk U, Ochniewicz P, Laszuk E, Tomczyk K, Garnuszek P
Curr Radiopharm
. 2021 May;
15(1):84-91.
PMID: 34053431
Background: The choice of mice strain can significantly influence the physiological distribution and may lead to an inadequate assessment of the radiopharmaceutical properties. Objective: This work aims to present how...
10.
Garnuszek P, Karczmarczyk U, Maurin M, Sikora A, Zaborniak J, Pijarowska-Kruszyna J, et al.
Int J Mol Sci
. 2021 Apr;
22(5).
PMID: 33800517
A new PSMA ligand (PSMA-D4) containing the Glu-CO-Lys pharmacophore connected with a new linker system (L-Trp-4-Amc) and chelator DOTA was developed for radiolabeling with therapeutic radionuclides. Herein we describe the...